Niioka, T.; Kagaya, H.; Saito, M.; Inoue, T.; Numakura, K.; Habuchi, T.; Satoh, S.; Miura, M.
Capability of Utilizing CYP3A5 Polymorphisms to Predict Therapeutic Dosage of Tacrolimus at Early Stage Post-Renal Transplantation. Int. J. Mol. Sci. 2015, 16, 1840-1854.
https://doi.org/10.3390/ijms16011840
AMA Style
Niioka T, Kagaya H, Saito M, Inoue T, Numakura K, Habuchi T, Satoh S, Miura M.
Capability of Utilizing CYP3A5 Polymorphisms to Predict Therapeutic Dosage of Tacrolimus at Early Stage Post-Renal Transplantation. International Journal of Molecular Sciences. 2015; 16(1):1840-1854.
https://doi.org/10.3390/ijms16011840
Chicago/Turabian Style
Niioka, Takenori, Hideaki Kagaya, Mitsuru Saito, Takamitsu Inoue, Kazuyuki Numakura, Tomonori Habuchi, Shigeru Satoh, and Masatomo Miura.
2015. "Capability of Utilizing CYP3A5 Polymorphisms to Predict Therapeutic Dosage of Tacrolimus at Early Stage Post-Renal Transplantation" International Journal of Molecular Sciences 16, no. 1: 1840-1854.
https://doi.org/10.3390/ijms16011840
APA Style
Niioka, T., Kagaya, H., Saito, M., Inoue, T., Numakura, K., Habuchi, T., Satoh, S., & Miura, M.
(2015). Capability of Utilizing CYP3A5 Polymorphisms to Predict Therapeutic Dosage of Tacrolimus at Early Stage Post-Renal Transplantation. International Journal of Molecular Sciences, 16(1), 1840-1854.
https://doi.org/10.3390/ijms16011840